Sheer Analytics And Insights Pvt. Ltd.

Saturday 10 September 2022

Preclinical Imaging Market is Expected to Reach $1.67 billion by 2032



According to a market report, published by Sheer Analytics and Insights, the global preclinical imaging market was valued at $0.87 billion in 2021 and it is expected to reach $1.67 billion at a CAGR of 5.9% between 2022 and 2032. Throughout the projection period, increasing demand from veterinary hospitals and educational institutions will assist to temper market expansion. The market will grow more quickly because of the sophisticated research infrastructure. Additionally, small animal imaging is a molecular imaging approach that investigates in vivo characterization and quantification of biological processes at the cellular and molecular levels. These methods track and record the spatiotemporal distribution of molecular or cellular activities directly or indirectly for use in biochemical, biological, diagnostic, or therapeutic applications. The surge in demand for non-invasive small animal imaging techniques is predicted to be the key growth driver for preclinical imaging technology during the research period. Therefore, these drivers are expected to accelerate market growth during the forecast period across several emerging nations globally. 

The best imaging modalities for small-animal in vivo applications include nuclear medicine methods (primarily positron emission tomography [PET] and single-photon emission computed tomography [SPECT]), optical imaging, micro-computed tomography (CT), micro magnetic resonance imaging (MRI), Photoacoustic tomography (PAT), and ultrasound. Each modality offers a unique set of advantages and disadvantages. To get around the inherent limitations of each imaging modality, multimodality devices—designed to provide additional information on the pathophysiological process under study—have quickly gained favor. Moreover, technology developments in molecular imaging, the rising need for non-invasive small animal imaging techniques, and an increase in preclinical research funding from both commercial and public organizations are the main drivers driving the growth of the preclinical imaging market. These primary factors would propel the market growth over the upcoming years.

Request a free PDF sample report: https://www.sheeranalyticsandinsights.com/request-sample/preclinical-imaging-market-21

A fast-growing multidiscipline, molecular imaging integrates molecular biology, chemistry, computer science, engineering, and medicine. It is capable of real-time, non-invasive viewing and quantification of physiological or pathological processes occurring at the cellular or molecular level in a living organism. Furthermore, by enhancing doctors' abilities to perform screening, surveillance, staging, prognosis, planning and therapy guidance, monitoring therapy efficacy, and assessing recurrence, multimodal molecular imaging can play a significant role in the clinical management of a variety of diseases. Therefore, these rising factors are projected to create more growth opportunities for the preclinical imaging market across the globe. 

However, the biggest barriers to the market's expansion are the limitations on animal testing imposed by laws that are enforced by groups that defend animal rights. Alternative techniques are quickly gaining acceptance, including in-vitro tests, micro-dosing, computer-based models, virtual drug testing, and the development of computerized databases for testing. On the other hand, non-invasive imaging methods like MRI and CT scans are growing in popularity. The COVID-19 outbreak had a substantial influence on the market in 2020, leading to a decline in the production of preclinical imaging devices as well as delays in their import and export, which significantly disrupted commerce. Various key players are focusing on expanding their business growth by implementing new strategies such as producing innovative products for multiple industries, especially in the medical sector. Mergers and acquisitions are one of the modern factors which would help many companies to build a strong position in the global market.  

Some new developments in the global preclinical imaging market:

  • On 10th May, 2022, Novel 7.4 and 9.4 Tesla Preclinical MRI Magnets are released by Bruker. Researchers can obtain high spatial and temporal resolution in preclinical imaging for non-invasive in vivo imaging on tiny rodents for research applications in oncology, neurology, cardiology, and infectious diseases. When doing functional MRI or high-resolution anatomical imaging of mouse brains, Bruker MRI equipment' excellent stability produces bright, clear pictures that are essential for investigating minute areas (fMRI).
  • On 7th April, 2022, with the addition of a hands-free, high-throughput Wide-field Preclinical Ultrasound imaging system, PerkinElmer broadens its array of in vivo devices. Through the utilization of two automated transducers positioned below the imaging stage, the Vega system eliminates problems with traditional hand-held ultrasound systems.

According to the study, key players dominating the global preclinical imaging market are Aspec Imaging (Israel), Aetos Technologies (U.S), Agilent Technologies (U.S), Bruker (U.S), Fujifilm (Japan), General Electric (U.S), Molecubes (Belgium), Mediso (Hungary), MR Solutions (U.K), Milavs BV (Netherlands), PerkinElmer (U.S), Siemens (Germany), Sumitomo Mitsui Financial Group (Japan), Topcon (Japan), Tri-foil Imaging (U.S), among others.   

The Global Preclinical Imaging Market Has Been Segmented Into:

The Global Preclinical Imaging Market – by Product Type:   

  • CT Imaging
  • Optical Imaging
  • Ultrasound Imaging
  • Reagents
  • Services
  • MRI Imaging
  • PET/SPECT Imaging
  • Others

The Global Preclinical Imaging Market – by Application Type:   

  • Research and Development
  • Drug Discovery

The Global Preclinical Imaging Market – by End-Use Type:

  • Biotech Companies
  • Research Institutes
  • Pharmaceutical Companies

The Global Preclinical Imaging Market – by Regions:  

North America

  • U.S.
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • Italy
  • U.K.
  • Russia
  • Rest of Europe Countries

Asia-Pacific

  • India
  • China
  • Japan
  • South Korea
  • North Korea
  • Rest of Asian Countries

LAMEA

  • Brazil
  • Saudi Arabia
  • Rest of LAMEA

Browse the full report at https://www.sheeranalyticsandinsights.com/market-report-research/preclinical-imaging-market-21

No comments:

Post a Comment